Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues

Nikolaos Papadopoulos, Maria Papavdi, Anna Pavlidou, Dimitris Konstantinou, Hariklia Kranidioti, George Kontos, John Koskinas, George V Papatheodoridis, Spilios Manolakopoulos, Melanie Deutsch, Nikolaos Papadopoulos, Maria Papavdi, Anna Pavlidou, Dimitris Konstantinou, Hariklia Kranidioti, George Kontos, John Koskinas, George V Papatheodoridis, Spilios Manolakopoulos, Melanie Deutsch

Abstract

Background: Only limited data concerning hepatitis B (HBV) and C viruses (HCV) coinfection are available. Direct-acting antivirals (DAAs) may be more effective for HCV clearance than interferon (IFN)-based regimens with a risk of HBV reactivation.

Methods: We retrospectively enrolled 40 HBV/HCV-coinfected patients to evaluate their clinical profile and treatment outcomes.

Results: Chronic dual infection was present in 25/40 (62.5%) patients, acute HCV superinfection in 5/40 (12.5%) patients and acute HBV superinfection in 10/40 (25%). Twenty-five patients (62.5%) were treated: 16/25 (64%) with IFN, 4/25 (16%) with nucleot(s)ide analogs (NUCs) and 5/25 (20%) with DAAs. Of the 16 patients treated with IFN-based therapy, 6 (37.5%) achieved both sustained virological response (SVR) and HBsAg clearance. Of the 4 patients treated with NUCs, one (25%) achieved both SVR and HBsAg clearance. All five patients treated with DAAs (100%) achieved SVR, while one case of HBV reactivation was recorded. Fifteen of the 40 patients (37.5%) did not receive any treatment. Eight of them (53.5%) presented with acute HBV superinfection: spontaneous HCV clearance was recorded in 5/8 (62.5%), while HBsAg clearance occurred in 6/8 (75%). Three of them (20%) presented with acute HCV superinfection; spontaneous HCV clearance was recorded in one of the three (33.5%). The other four patients (26.5%) presented with dual HBV/HCV infection.

Conclusions: A significant proportion of patients presented with active HBV replication. Treatment with DAAs seems to be efficacious for HCV eradication. However, clinicians should be aware of HBV reactivation. HBV superinfection may lead to both HBsAg and HCV clearance.

Keywords: Hepatitis B; direct-acting antivirals; hepatitis C; interferon.

Conflict of interest statement

Conflict of Interest: None

References

    1. Chakravarti A, Verma V, Jain M, Kar P. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease:a study from tertiary care hospital. Trop Gastroenterol. 2005;26:183–187.
    1. Mekky MA, Nasr AM, Saleh MA, et al. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients. Arab J Gastroenterol. 2013;14:143–147.
    1. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol. 2003;39:1036–1041.
    1. Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38–41.
    1. Senturk H, Tahan V, Canbakan B, et al. Clinicopathologic features of dual chronic hepatitis B and C infection:a comparison with single hepatitis B, C and delta infections. Ann Hepatol. 2008;7:52–58.
    1. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection:epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol. 2015;28:221–228.
    1. Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol. 2002;37(Suppl 13):65–68.
    1. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol. 2000;95:2978–2980.
    1. Yan BM, Lee SS. Acute coinfection with hepatitis B and hepatitis C viruses. Can J Gastroenterol. 2005;19:729–730.
    1. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int. 2009;3:517–525.
    1. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc. 2005;104:783–791.
    1. Pallás JR, Fariñas-Alvarez C, Prieto D, Delgado-Rodríguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999;15:699–704.
    1. Nguyen LH, Ko S, Wong SS, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology. 2011;53:1839–1845.
    1. Raptopoulou M, Papatheodoridis G, Antoniou A, et al. Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B:a multicentre Greek study. J Viral Hepat. 2009;16:195–202.
    1. Chen F, Zhang J, Wen B, et al. HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection. Sci Rep. 2016;6:39409.
    1. Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferon αand ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut. 2014;63:506–514.
    1. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–576.
    1. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.
    1. Sagnelli E, Coppola N, Pisaturo M, et al. HBV superinfection in HCV chronic carriers:a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090–1097.
    1. Gruener NH, Jung MC, Ulsenheimer A, et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol. 2002;37:866–869.
    1. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304–1306.
    1. Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27–36.
    1. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents:a systematic review and meta-analysis. Hepatology. 2017;66:13–26.
    1. Mücke VT, Mücke MM, Peiffer KH, et al. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther. 2017;46:432–439.
    1. Londoño MC, Lens S, Mariño Z, et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther. 2017;45:1156–1161.
    1. Potthoff A, Berg T, Wedemeyer H HEP-NET B/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009;44:1487–1490.
    1. [Accessed March 5 2018]. .
    1. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus:a review of cases reported to the U.S. food and drug administration adverse event reporting system. Ann Intern Med. 2017;166:792–798.
    1. European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
    1. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere